Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Frequency Ultrasound and ADSCs in PAD
NCT02756884Phase 1Completed
- Sponsor
- Arkansas Heart Hospital
- Start
- Jun 2015
- Primary completion
- Jan 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adipose derived mesenchymal stromal cells in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Arkansas Heart Hospital. Primary endpoint: Incidence of adverse events at 6 months. Started Jun 2015; status: completed.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02756884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756884.